Drugs resistance data from a phase 1b switch study of lenacapavir plus two bNAbs in people who were already suppressed on standard ART included high-level drug resistance in 3/30 participants with low-level viral rebound, with one developing treatment failure at week 26.
Genotypic and phenotypic analyses of proviral gag and envelope DNA were performed at baseline and viral failure and results are published in an open access paper in JID.
Read the full news story at HIV i-Base.
Source : HIV i-Base
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.